Monitor for FDA 510(k) submission and any clinical data readouts from SYMON-II as the next catalysts. The cash runway into Q2 2027 provides a buffer but the stock remains binary on regulatory outcomes.
Price Chart
Executive Summary
Bluejay Diagnostics reported Q2 2026 results, highlighting the completion of SYMON-II pivotal study enrollment (750 patients) and a strengthened balance sheet with ~$9.6M cash, extending the runway into Q2 2027. The company is pre-revenue with no regulatory clearance, and the filing is a routine operational update with no financial results or guidance provided, making it neutral for the stock.
Key Facts
- SYMON-II pivotal clinical study completed targeted enrollment of 750 patients.
- Cash and cash equivalents were approximately $9.6 million at June 30, 2026, up from $5.2 million at December 31, 2025.
- Net cash from financing activities in H1 2026 was ~$7.7 million, including ~$7.6 million from a June 2026 private placement.
- Current cash resources estimated to fund operations through Q2 2027.
- Company is advancing toward a planned 510(k) submission and has signed a US manufacturing contract.
Financial Impact
Cash balance increased from ~$5.2M to ~$9.6M; net cash from financing of ~$7.7M in H1 2026.
Risk Factors
- No revenue or regulatory clearance for the Symphony System.
- Dependence on FDA 510(k) clearance for commercialization.
- Cash runway only through Q2 2027; further dilution likely if regulatory timeline extends.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-088701 |
| Document: ea030188801ex99-1.htm | 0001213900-26-088701 |
| Document: 0001213900-26-088701-index-headers.html | 0001213900-26-088701 |
| Document: 0001213900-26-088701-index.html | 0001213900-26-088701 |
| Document: 0001213900-26-088701.txt | 0001213900-26-088701 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 8-K | $0.8323 | awaiting T+20 | — | $0.5918 (−28.90%) |
Oct 6, 2026 21d ago | 8-K | $0.8107 | awaiting T+20 | — | $0.5918 (−27.00%) |
Aug 13, 2026 10w ago | 8-K | $1.06 | awaiting T+20 | — | $0.5918 (−44.17%) |
Aug 13, 2026 10w ago | Press Release | $1.06 | awaiting T+20 | — | $0.5918 (−44.17%) |
Jul 22, 2026 13w ago | 8-K | $1.14 $0.9393 | ▼ −17.61% | ▼ −20.91% | $0.5918 (−48.09%) |
Jul 13, 2026 15w ago | 3 | $1.22 $0.9872 | ▼ −19.08% | ▼ −22.27% | $0.5918 (−51.49%) |
Jul 10, 2026 15w ago | 3 | $1.45 $1.07 | ▼ −26.21% | ▼ −28.63% | $0.5918 (−59.19%) |
Jun 29, 2026 17w ago | EFFECT | $1.44 $1.03 | ▲ +28.47% | ▲ +28.19% | $0.5918 (+58.90%) |
Jun 17, 2026 18w ago | S-3 | $4.46 $1.30 | ▲ +70.85% | ▲ +71.39% | $0.5918 (+86.73%) |
Jun 9, 2026 19w ago | 8-K | $4.49 $1.40 | ▼ −68.82% | ▼ −72.44% | $0.5918 (−86.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers